Table 1 Study characteristics

Fogari et al., 2010 [20]

Randomized, double-blind, parallel-group, up-titration, multicenter, multinational, phase III

Olmesartan

Moderate to severe hypertension, male or female patients, mean age 55.6

16 weeks

285

556

40

40/12.5, 40/25

Benz et al., 1998 [21]

Randomized, double-blind, multiple dose, placebo controlled, multifactorial, parallel

Valsartan

Uncomplicated essential hypertension, male or female patients, mean age 52 (22-86)

8 weeks

198 (99, 99)

379 (96, 92, 97, 94)

80, 160

80/12.5, 80/25, 160/12.5, 160/25

Edes, 2009 [22]

Randomized, double-blind, parallel-group study

Candesartan

Mild to moderate primary hypertension, male or female patients, mean age 53

8 weeks, 4 weeks follow-up

465

492

32

32/25

Kwon et al., 2013 [23]

Open-label, randomized, prospective cross-over study

Candesartan

Never treated primary hypertension, male or female patients, mean age 50

8 weeks

25 (4 weeks)

15

13

8

8/25

8/12.5

Lacourciere and Martin, 2002 [24]

Prospective, randomized, double-blind, parallel-group study

Telmisartan

Mild-to-moderate essential hypertension, male or female patients, mean age 54.1 (28-79)

8 weeks

167

160

40

40/12.5

Lacourciere et al., 2001 [25]

Multicenter, prospective, randomized, double-blind, parallel-group study

Telmisartan

Mild-to-moderate, essential hypertension and inadequate BP control, male or female patients, mean age 55.6 (20-79)

8 weeks

245

246

80

80/12.5

Lacourciere et al., 2005 [26]

Randomized, double blind, 3-arm, parallel group study

Valsartan

Stage 2 or 3 systolic hypertension (SBP ≥ 160 mmHg and ≤ 200 mmHg) with or without other CV risk factors, male or female patients, mean age 60.8

8 weeks

261

513 (258, 255)

80, 160

160/12.5, 160/25

Makita et al., 2009 [27]

Randomized, parallel-group study

Candesartan/valsartan vs telmisartan

Hypertensive outpatients treated with an ARB, candesartan or valsartan, male or female patients, mean age 69.3

12 weeks

32

32

8 or 80

40/12.5

Rhee et al., 2015 [28]

Multicenter, randomized, active-controlled, double-blind, parallel-group, dose-titration trial

Fimasartan

Mild to moderate primary hypertension, male or female patients, mean age 55.3

8 weeks

88

175

60

60/12.5

Sachse et al., 2002 [29]

Multicenter, prospective, randomized, double-blind, parallel group study

Eprosartan

Mild to moderate primary hypertension, male or female patients

mean age 58.7

8 weeks, 4 weeks follow-up

157

152

600

600/12.5

MacKay et al., 1996 [32]

Multicenter, randomized, double-blind, parallel-group study

Losartan

Essential hypertension, male or female patients, mean age 55 (22-79)

8 weeks, 4 weeks follow-up

122

125, 114

50

50/6.25, 50/12.5

Sica et al., 2012 [33]

Phase 3, randomized, double-blind, factorial study

Azilsartan

Mild to moderate primary hypertension, male or female patients, mean age 57

8 weeks

470 (155, 153, 162)

928 (156, 147, 153, 154, 156, 162)

20, 40, 80

20/12.5, 40/12.5, 80/12.5, 20/25, 40/25, 80/25

Cushman et al., 2012 [34]

Randomized, double-blind, forced-titration study

Azilsartan+ chlorthalidone; olmesartan+ hydrochlorothiazide

Primary hypertension, male or female patients, mean age 57

12 weeks

364

355, 352

40/25

40/25, 80/25

Cushman et al., 2018 [35]

Randomized, double-blind, parallel-group study

Azilsartan+ chlorthalidone; olmesartan+ hydrochlorothiazide

Primary hypertension, male or female patients, mean age 57

8 weeks

356

372, 357

40/25

40/25, 80/25

Neutel et al., 2017 [36]

Phase 3, randomized, parallel-group, open-label, multicenter, multinational study

Azilsartan+ chlorthalidone; olmesartan+ hydrochlorothiazide

Stage 2 essential hypertension, male or female patients, mean age 58.5 (> 45)

52 weeks

419

418

40/25

80/25